Provided herein is a portable test device, mass manufacture method and method of use for identification of at least one target drug of abuse. The portable detection kit can include a catalytic reagent, a solid support carrier, and an absorbent material. The colorimetric reagent and the catalytic reagent can be are affixed to the solid support carrier to form a reaction zone thereon. The colorimetric reagent and the catalytic reagent are configured to undergo chemical reaction with at least one target drug of abuse to produce a visible color change. The at least one target drug of abuse is selected from the group consisting of nicotine, cannabinoids, amphetamines, opioids, or cocaine. A target drug of abuse can be on vaping device surfaces and/or within vaping liquid formulations.

The present invention relates to a kit comprising: a) an ampoule; b) a material comprising a hemp plant or parts thereof; and c) a color indicator capable of reacting by contacting the hemp plant and/or at least a part thereof to change the color of the color indicator, wherein the material and the color indicator are disposed in the ampoule; and a method for qualitatively and/or quantitatively detecting one or more substance(s) contained in the hemp plant using the kit.

A home testing kit used to collect a blood sample of the user and a method of blood analysis used to calculate correct mixtures of THC and CBD for each patient's desired therapeutic benefit.

The present invention discloses novel non-natural and modified peptides acting as cannabinoid (CB) receptors ligands, especially CB1 and/or CB2, useful as modulators of its activity; they are also described as a kit and a process in vitro for evaluating the binding to CB receptors, uses and pharmaceutical composition for modulating the CB receptors activity. The invention covers the non-natural peptide of SeqID:1 and those having at least 70% similarity related to the same, including as achievements specialty useful of the invention the non-natural peptides of SeqID:2, SeqID:3, SeqID:4, SeqID:5, SeqID:6.

Systems and methods are disclosed to determine that a cannabis plant has been cultivated under desired cultivation conditions. Quantitative processes are disclosed, based on stable carbon isotope ratio analysis, and using modeling constraints and Bayesian approaches to produce a likelihood that a cannabis plant was cultivated under desired conditions (e.g., indoors), and provide a quantitative estimate of the average CO.sub.2 concentration in the growth environment.

Devices, assays and methods for detecting analytes in a sample are provided. Biosensor devices include a biosensor interface that includes enzyme-conjugated molecules, antibodies and an enzyme driven redox cycle coupled to an electrically conductive electrode for signal amplification. The biosensor devices are easily adaptable to a variety of assay formats, a variety of target analytes and provide real-time measurements combined with high sensitivity and high specificity for the analyte.

A detection device for cannabinoid use including a base unit and a display screen disposed on the base unit. A central processing unit and a tetrahydrocannabinol testing device are disposed within the base unit. A testing slot is disposed on a bottom portion of the base unit, with a back end of the testing slot disposed within the tetrahydrocannabinol testing device. Each of a plurality of testing strips is slidably and removably disposed within the testing slot. A printer has a pair of T-shaped attachment extensions. Each of the pair of attachment extensions and a universal serial bus plug disposed on the printer simultaneously removably and slidably engages each of a pair of attachment slots and a universal serial bus port disposed on the base unit, respectively. The tetrahydrocannabinol testing device is configured to analyze and calculate the presence and amount of tetrahydrocannabinol in a person's bloodstream.

The present invention relates to determining the chemotype profile of cannabis plant material through determining cannabinoid content of the plant material using near infrared spectroscopy. The invention also involves the training of a classifier to determine the chemotype profile of a cannabis plant from the spectroscopic data.

Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

A method for quantification of the concentration of one or more cannabinoid compounds in a liquid sample is provided. The method involves contacting the liquid sample with at least one cannabinoid-sensitive visualization reagent, allowing the at least one cannabinoid-sensitive visualization reagent to develop for a defined amount of time; and comparing the resulting color change of the at least one cannabinoid-sensitive visualization reagent to a calibrated quantification reference chart.